NCT06969170 - Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

August 30, 2026

Conditions

Generalized Anxiety Disorder (GAD)

Interventions

DRUG

Psilocybin (drug)

Psilocybin 3mg Po (oral solution) administered daily for 28 days (Open-Label Run-in Phase) followed by Psilocybin 3mg Po (oral solution) OR Placebo for 28 days (Double-Blind Treatment Phase) in patients with Generalized Anxiety Disorder(GAD)

OTHER

Placebo

Sucralose 0.2% oral solution

Trial Locations (1)

K7L 2V7

RECRUITING

Kingston General Health Research Institute, Kingston